Patents by Inventor Jinfeng XUE

Jinfeng XUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TCR-enriched clonotype, acquisition method and use thereof
    Patent number: 12252526
    Abstract: Disclosed are TCR-enriched clonotypes, and an acquisition method and use thereof. Amino acid sequences of the TCR-enriched clonotypes are: CAANRGSGYSTLTF (SEQ ID NO: 1)_CSARGERGEKLFF (SEQ ID NO: 2), CASSSGGSYIPTF (SEQ ID NO: 3)_CASSLAGGHETQYF (SEQ ID NO: 4), CAVNSYNTDKLIF (SEQ ID NO: 5)_CATSREEDNTYEQYF (SEQ ID NO: 6), CAVGGNEKLTF (SEQ ID NO: 7)_CASSQGTGRSSPLHF (SEQ ID NO: 8), or CAASAVGGAQKLVF (SEQ ID NO: 9)_CATSRGTLYGYTF (SEQ ID NO: 10), respectively. The TCR-enriched clonotypes can be used for vaccine development.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 18, 2025
    Assignee: HUNAN YUANPIN CELL TECHNOLOGY CO. LTD.
    Inventors: Zhigang Xue, Jinfeng Xue, Ning Yi, Bo Lv, Chanyi Li, Lingbin Qi, Weilin Li
  • TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOF
    Publication number: 20210403529
    Abstract: Disclosed are TCR-enriched clonotypes, and an acquisition method and use thereof. Amino acid sequences of the TCR-enriched clonotypes are: CAANRGSGYSTLTF_CSARGERGEKLFF, CASSSGGSYIPTF_CASSLAGGHETQYF, CAVNSYNTDKLIF_CATSREEDNTYEQYF, CAVGGNEKLTF_CASSQGTGRSSPLHF, or CAASAVGGAQKLVF_CATSRGTLYGYTF, respectively. The TCR-enriched clonotypes can be used for vaccine development.
    Type: Application
    Filed: September 15, 2021
    Publication date: December 30, 2021
    Inventors: Zhigang XUE, Jinfeng XUE, Ning YI, Bo LV, Chanyi LI, Lingbin QI, Weilin LI